Show simple item record

dc.contributor.authorO'Reilly, Aen_US
dc.contributor.authorLarkin, Jen_US
dc.date.accessioned2017-05-26T15:40:26Z
dc.date.issued2017-03en_US
dc.identifier.citationExpert review of clinical pharmacology, 2017, 10 (3), pp. 251 - 262en_US
dc.identifier.issn1751-2433en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/666
dc.identifier.eissn1751-2441en_US
dc.identifier.doi10.1080/17512433.2017.1289840en_US
dc.description.abstract<h4>Introduction</h4>In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited. Recently a number of agents have demonstrated efficacy in this setting. Here in we profile one such therapy, the combination of lenvatinib and everolimus, and discuss the expanded options for therapy available in this setting. Areas covered: In this review, we discuss current algorithms for treatment of mRCC in both the first-line and second-line setting. We discuss the recent addition of cabozantinib and nivolumab, in the second line setting, to the market. Lenvatinib's pharmacology, clinical efficacy and toxicity profile is discussed. A comprehensive literature review was performed using PUBMED. Expert commentary: The current treatment algorithms for mRCC will likely see significant change in the coming years. The addition of immunotherapy to our treatment options in mRCC is of particular importance. Future trials examining the use of immunotherapy, both as monotherapy and in combination with VEGF targeted therapy, will likely be a dominant influence in the therapeutic landscape of mRCC. Progress in terms of the rapid expansion of available active therapies in mRCC needs to be balanced with current deficiencies in terms of predictive biomarkers.en_US
dc.formatPrint-Electronicen_US
dc.format.extent251 - 262en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectHumansen_US
dc.subjectCarcinoma, Renal Cellen_US
dc.subjectKidney Neoplasmsen_US
dc.subjectDisease Progressionen_US
dc.subjectPhenylurea Compoundsen_US
dc.subjectQuinolinesen_US
dc.subjectAngiogenesis Inhibitorsen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectAlgorithmsen_US
dc.subjectEverolimusen_US
dc.titleLenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/17512433.2017.1289840en_US
rioxxterms.licenseref.startdate2017-03en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfExpert review of clinical pharmacologyen_US
pubs.issue3en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume10en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record